Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 10;8:306. doi: 10.3389/fonc.2018.00306

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © Barros, Kupper, Aguiar Junior, de Mello, Begnami, Chojniak, de Souza, Torrezan and Carraro.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Timeline of patient's treatment, follow-up and ctDNA mutation levels during disease progression. The upper panel shows the frequencies of tumor mutations detected in each plasma sample, and hepatic lesion size throughout the course of palliative chemotherapy. An increase in KRAS and TP53 mutation frequencies observed in PS4 preceded significant increases in tumor marker frequencies in PS5 and PS6. Sequential CT measurements were suggestive of disease stability throughout the treatment period. The lower panel shows the patient's course of treatment (FOLFOX followed by FOLFIRI) with surgery date and serial PS collection. PS, plasma sample; CT, computed tomography; *, patient death.

HHS Vulnerability Disclosure